Johnson & Johnson : advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA
Media contacts: Investor contact: ...
Source: marketscreener.com
Yusri Elsayed News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Yusri Elsayed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Yusri Elsayed Today - Breaking & Trending Today
Johnson & Johnson procures Ambrx Biopharma to Develop Oncology Portfolio
#industry #news #UK #2024 #insights #zenopa #recruitment #Johnson #Johnson #Ambrx #Biopharma #Oncology #Portfolio #acquired #platform #prostate #cancer
Source: zenopa.com
Golden Cross Alert: Johnson & Johnson Shines With Ambrx Deal, Bullish Technical Signal - Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson stock down 1.22% in 6 months, up 5.57% in a year, and 3% YTD. Recent acquisition of Ambrx Biopharma boosts stock. Golden Cross signals trend reversal.
Source: benzinga.com
Johnson & Johnson to acquire Ambrx Biopharma
The acquisition will advance next generation antibody drug conjugates to transform the treatment of cancer.
Source: drugstorenews.com
Johnson & Johnson to Acquire Ambrx for $2 Billion
The acquisition strengthens Johnson & Johnson's oncology portfolio.
Source: powderbulksolids.com